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Abstract Smart matrices are required in bone tissue-engineered grafts that provide an optimal environment for cells
and retain osteo-inductive factors for sustained biological activity. We hypothesized that a slow-degrading
heparin-incorporated hyaluronan (HA) hydrogel can preserve BMP-2; while an arterio–venous (A–V) loop
can support axial vascularization to provide nutrition for a bio-artificial bone graft. HA was evaluated for
osteoblast growth and BMP-2 release. Porous PLDLLA–TCP–PCL scaffolds were produced by rapid
prototyping technology and applied in vivo along with HA-hydrogel, loaded with either primary osteoblasts
or BMP-2. A microsurgically created A–V loop was placed around the scaffold, encased in an isolation
chamber in Lewis rats. HA-hydrogel supported growth of osteoblasts over 8 weeks and allowed sustained
release of BMP-2 over 35 days. The A–V loop provided an angiogenic stimulus with the formation of
vascularized tissue in the scaffolds. Bone-specific genes were detected by real time RT-PCR after 8 weeks.
However, no significant amount of bone was observed histologically. The heterotopic isolation chamber in
combination with absent biomechanical stimulation might explain the insufficient bone formation despite
adequate expression of bone-related genes. Optimization of the interplay of osteogenic cells and osteo-
inductive factors might eventually generate sufficient amounts of axially vascularized bone grafts for
reconstructive surgery.
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13 Abstract Smart matrices are required in bone tissue-
14 engineered grafts that provide an optimal environment for
15 cells and retain osteo-inductive factors for sustained bio-
16 logical activity. We hypothesized that a slow-degrading
17 heparin-incorporated hyaluronan (HA) hydrogel can pre-
18 serve BMP-2; while an arterio–venous (A–V) loop can
19 support axial vascularization to provide nutrition for a bio-
20 artificial bone graft. HA was evaluated for osteoblast
21 growth and BMP-2 release. Porous PLDLLA–TCP–PCL
22 scaffolds were produced by rapid prototyping technology
23 and applied in vivo along with HA-hydrogel, loaded with
24 either primary osteoblasts or BMP-2. A microsurgically
25 created A–V loop was placed around the scaffold, encased
26 in an isolation chamber in Lewis rats. HA-hydrogel sup-
27 ported growth of osteoblasts over 8 weeks and allowed
28 sustained release of BMP-2 over 35 days. The A–V loop
29provided an angiogenic stimulus with the formation of
30vascularized tissue in the scaffolds. Bone-specific genes
31were detected by real time RT-PCR after 8 weeks.
32However, no significant amount of bone was observed
33histologically. The heterotopic isolation chamber in com-
34bination with absent biomechanical stimulation might
35explain the insufficient bone formation despite adequate
36expression of bone-related genes. Optimization of the
37interplay of osteogenic cells and osteo-inductive factors
38might eventually generate sufficient amounts of axially
39vascularized bone grafts for reconstructive surgery.
40
412Abbreviations
43HA Hyaluronic acid/hyaluronan hydrogel
44BMP Bone morphogenetic protein
45CT Computerized tomography
46A–V Arterio–venous
47PLDLLA Poly(L-lactide-co-D,L-lactide)
48PCL Poly(e-caprolactone)
49TCP b-Tri-calcium phosphate
50
51
521 Introduction
53Bone tissue engineering is based on the application of
54mechanically stable osteo-conductive scaffolds, osteogenic
55cells, and osteo-inductive growth factors [1]. Although
56autologous bone grafts represent the gold standard for the
57treatment of bone defects, a number of approaches
58employing osteo-conductive biomaterials had been descri-
59bed recently, in particular when massive bone loss was
60present. The creation of large constructs with full viability
61and functional activity still presents a major challenge.
62Since cells cannot survive at a distance of more than
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63 200–500 lm from a capillary, it is imperative for tissue-
64 engineered grafts to be well perfused by a rich vascular
65 network [2, 3]. In addition to the survival of cells, vascu-
66 larization is pre-requisite even for their differentiation [4].
67 In the majority of cases, host blood vessels grow into a
68 biomaterial in a random fashion after implantation in vivo, a
69 process called extrinsic vascularization. Transfer to the
70 defect site, though possible, is usually associated with
71 destruction of the vascular network. Thereafter, random
72 network formation among graft and host capillaries is
73 essential for the survival of the graft. On the contrary, a graft
74 pre-vascularizedwith a surgically createdA–V loop forms an
75 axially vascularized tissue [5]. This type of vascularization is
76 desired by reconstructive surgeons because, similarly as in
77 free flap transfer, it can be transferred to the defect site using
78 microsurgical techniques [6]. After implantation, these tis-
79 sues are immediately vascularized with complete survival of
80 the graft. An axially vascularized bioartificial bone graft was
81 successfully generated recently by our group using an A–V
82 loop as a vascular carrier [5]. The same technology might be
83 further extended for a large bone graft in a sheep model [7],
84 with the addition of suitable osteo-inductive factors.
85 Bone induction is a complex process involving chemo-
86 taxis, mitosis, and differentiation orchestrated by a number
87 of cytokines and growth factors in a sequential manner
88 starting from wound healing to bone remodeling [8].
89 A typical bone induction process takes almost 28 days after
90 bone loss, with the mesenchymal stem cell (MSC) attach-
91 ment on day three, while vascular invasion starting on day
92 nine [9]. The chemotactic factors induce migration of
93 osteo-progenitor cells to the local site followed by induc-
94 tion of differentiation towards bone lineage and secretion
95 of bone matrix proteins by bone-inducing growth factors,
96 especially BMP-2. Additional BMP group of proteins and
97 VEGF govern cell proliferation and bone vascularization to
98 make viable osseous tissue [8].
99 Bone morphogenetic proteins (BMP-2 s) are part of the
100 TGF-b group of highly active osteoinducing proteins and
101 they played a key role in the creation of many tissue
102 engineered bone grafts in the past [10, 11]. Considering its
103 highly potent action, a controlled release in vivo is
104 imperative and deviation of the release in any side can
105 either result in insufficient bone formation or lead to
106 undesired ectopic bone formation, compromising the
107 vitality of nearby tissues [11, 12]. Within 14 days of local
108 BMP-2 application, its concentration decreases to 5% of
109 initial dosage [13]. When BMP-2 is applied as a solution
110 in vivo, it is released into the blood stream and loses its
111 bioactivity within hours after rapid degradation and may
112 not be effective for bone induction [14].
113 One major goal for drug delivery systems is to maintain
114 BMP-2 at the site of bone loss and release it in a controlled
115 and continuous manner to act on migrating osteogenic cells
116to induce bone formation [13]. The release has to be
117predictable and at physiological concentrations; the BMP-
118responsive cells should be located nearby. Failure of clini-
119cal trials has been reported when its bioavailability was
120lower than the physiological requirement of the bone
121healing process because of its rapid degradation after
122release [15]. To circumvent the problem, increased amounts
123of BMP-2 at supra-physiologic doses may be given. In
124addition to increased cost, this may induce ossification
125impinging on nearby vital neurovascular structures and life-
126threatening swelling and disability [16]. Though type I
127collagen is most commonly used for BMP-2 as a carrier
128[11], a number of other carrier systems have been suggested
129[13]. In some cases, carrier systems such as fibrin glue are
130used to inhibit BMP-2 diffusion out of the applied site to
131prevent soft tissue ossification [12]. Additionally, a carrier
132acts more than just delivering BMP-2 with documented
133supra-additive effect of a carrier and BMP-2 forming a
134favorable three-dimensional extracellular matrix.
135Hyaluronan (HA) hydrogel is osteo-conductive and
136osteo-integrative. However, for its osteo-inductive action,
137special growth factors need to be applied. Currently, BMP-2
138and BMP-7 have been approved with type I collagen carrier,
139but other carriers may be superior in terms of efficacy [17].
140Hyaluronan has been shown to protect growth factors in
141vitro for more than 4 weeks from proteolysis [18]. It has
142also been shown to release active growth factors slowly in
143the presence of heparin [18]. Heparin can prolong the sta-
144bility of BMP-2 almost 20-fold and can produce ectopic
145bone with only 1 lg of BMP-2, avoiding the use of sig-
146nificantly increased doses [19]. However, for the effective
147action of BMP-2, angiogenesis and vascular invasion must
148precede before ossification [9]. Exploiting the ability of
149BMP-2 to induce ectopic bone, heparin-incorporated hyal-
150uronic acid hydrogel can be utilized for its delivery.
151In this experiment, we hypothesize that an axially vas-
152cularized ectopic tissue-engineered bone graft can be
153fabricated with an A–V loop surrounding the PLDLLA–
154TCP–PCL-Hyaluronan scaffold-hydrogel composite. The
155aim of this study was twofold: firstly, to evaluate the BMP-
1562 release capacity of the system and growth and survival of
157primary osteoblasts in vitro; secondly, to investigate pro-
158gress of vascularization and formation of bone tissue
159within the composites in vivo following application of
160different concentrations of BMP-2 or primary osteoblasts.
1612 Materials and methods
1622.1 Scaffold fabrication
163The scaffolds were fabricated using the fused deposition
164modeling (FDM) principle [20] utilizing three different
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165 materials: PLDLLA (Boehringer-Ingelheim, Ingelheim am
166 Rein, Germany), PCL (Absorbable Polymers, US), TCP
167 (Progentix, MB Bilthoven, Netherlands), in a ratio of 64,
168 16, and 20% by weight, respectively. The strength is pro-
169 vided by the bioceramic component, while the polymer
170 part enables plasticity and ease of fabrication. The fabri-
171 cation was by an in-house rapid prototyping (RP) system,
172 namely the screw extrusion system (SES), similar to FDM
173 [20]. The details of the fabrication method are described
174 elsewhere [21]. Briefly, it exploits a layer-by-layer fabri-
175 cation technique to assemble three-dimensional (3D)
176 structures by depositing two-dimensional (2D) supporting
177 struts based on specified lay-down patterns to assemble the
178 whole structure. Material is fed into the top of the barrel
179 chamber, heated to a molten liquefied state at 120C and
180 transported towards a 400 lm nozzle with aided displace-
181 ment and pressure from the turning screw feed.
182 Scaffold sheets of 50 9 50 9 1.5 mm
3 were fabricated
183 with a 0–90 lay-down pattern. Discs with 8 mm diameter
184 were punched out from it and fabricated into bobbin-shaped
185 constructs (Fig. 1). The scaffolds were uniformly treated
186 with 5 M sodium hydroxide for 5 min and rinsed with
187 de-ionized water to yield a hydrophilic and corrugated sur-
188 face for improved cell attachment [22]. They were sterilized
189 in 70% ethanol overnight followed by UV light for 2 h. The
190 biomechanical properties of a comparable composite scaf-
191 fold were found to be suitable for bone tissue engineering,
192 showing excellent compatibility with MSCs [21].
193 2.2 Osteoblast culture and analysis in hyaluronan-
194 based hydrogel
195 Primary osteoblasts were isolated from long bones of male
196 Lewis rats as described elsewhere [23]. In brief, after sac-
197 rificing the rats at 4–8 weeks age, the long bones were col-
198 lected and serially digested in sterile collagenase-II (554
199 U/ml, Biochrom AG, Berlin, Germany) in 19 PBS. Subse-
200 quently, the cells were cultured in flasks (COSTAR, Cam-
201 bridge, USA), maintained at 37C and 5% CO2 with twice
202 weekly media change. Only second passage cells were
203 seeded into the scaffold for in vitro and in vivo evaluation.
204The hyaluronan-based (HA) hydrogel (Extracel-HP,
205Glycosan BioSystems, Salt Lake City, Utah) was supplied as
206a kit consisting of three components, namely thiol-modified
207hyaluronan and heparin, thiol-modified gelatine, and thiol-
208modified cross-linker, polyethylene glycol diacrylate. The
209components were prepared with distilled water at 37C
210under aseptic conditions and were mixed at 2:2:1 ratio,
211respectively, according to the manufacturer’s recommen-
212dations. The osteoblasts were mixed in the hydrogel such
213that 100 ll of the hydrogel, aliquoted in each well of 96-well
214culture plate, contained 10,000 osteoblasts. The cells were
215cultured in a 37C incubator with 5% CO2 with 100 ll of
216media. The medium was changed twice weekly. Osteoblasts
217in HA were observed for 8 weeks under inverted light
218microscope (Leica DMIL, Weltzlar, Germany).
219The hyaluronan-osteoblast specimens were analyzed by
220AlamarBlue (Biosource Int., Camarillo, CA) assay. Each
221week, culture medium was aspirated and 150 ll of culture
222medium with 5% AlamarBlue was added to the specimens
223and incubated for 4 h at 37C. Absorbance was then
224measured with a plate reader (SPECTRAmax 190,
225Molecular Devices, Sunnyvale, CA, USA) at wavelengths
226of 570 and 600 nm. The percentage of AlamarBlue
227reduction was subsequently calculated as advised by the
228manufacturer.
229Cell proliferation was evaluated using PicoGreen DNA
230quantification assay (Molecular Probes, Invitrogen GmbH,
231Karlsruhe, Germany) at 4 and 8 weeks as advised by the
232manufacturer. Specimens were thoroughly destroyed with
233lysis buffer (10 mM Tris (pH 7.0), 1 mM EDTA, and
2340.2% v/v triton X-100; all from Sigma-Aldrich GmbH,
235Steinheim, Germany). Fluorescence of specimen wells was
236measured with a fluorescent microplate reader (Genios,
237Tecan Group Ltd, Maennedorf, Switzerland) at excitation
238and emission wavelengths of 485 and 535 nm, respec-
239tively, corrected with blanks.
240To visualize viable and non-viable cells, osteoblasts
241were labeled with fluorescent probes. The osteoblast-
242seeded hydrogels were washed with 19 PBS and incubated
243with 2 lg/ml fluorescein diacetate (FDA) (Molecular
244Probes Inc., Eugene, USA) in 19 PBS, for 15 min at 37C.
Fig. 1 a Schematic diagram of
the bobbin-shaped scaffold.
b The scaffold showing high
porosity and a central groove for
accommodating the A–V loop
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245 They were gently rinsed twice in 19 PBS and placed in
246 20 lg/ml propidium iodide (PI) solution (Invitrogen
247 GmbH, Karlsruhe, Germany) for 2 min at room tempera-
248 ture. After thorough rinsing in 19 PBS, the specimens
249 were kept in 19 PBS and viewed under a fluorescent
250 microscope (Axiovert 25, Carl-Zeiss AG, Goettingen,
251 Germany). The viable cell cytoplasms were labeled green,
252 while non-viable cell nuclei were labeled red.
253 2.3 Release kinetics of rhBMP-2 from hyaluronan-
254 based hydrogel
255 The rhBMP-2 (INFUSE bone graft, Medtronics, Minne-
256 apolis, USA) was reconstituted to final concentration of
257 3.33 lg/ll in PBS. 10 lg of rhBMP-2 was incorporated in
258 50 ll of hyaluronan hydrogel. All disc shaped hydrogels
259 were uniformly polymerized to get a thickness of 4 mm
260 and a diameter of 5 mm. The BMP-2 containing hydrogel
261 discs (n = 3) were placed in 1 ml of pre-warmed PBS until
262 35 days from the start of the experiment. At different time
263 points (1, 2, 4, 6, and 24 h and 2, 4, 7, 10, 14, 17, 21, 28,
264 and 35 days), 100 ll of PBS were sampled and replaced
265 with an equal amount of fresh PBS after the scaffolds were
266 kept on a shaker for 3 min. The collected 100 ll of PBS
267 were kept in -80C and the rhBMP-2 content was mea-
268 sured by rhBMP-2 ELISA kit (Quantikine, R&D systems,
269 Minneapolis, MN, USA). The values were calculated from
270 the standard curve. The cumulative release was calculated
271 for each time point.
272 2.4 In vivo experiments
273 Twenty-four inbred male Lewis rats (Charles-River, Sulz-
274 feld, Germany) weighing 200–300 g were used with
275 approval by the animal care committee of the University of
276 Erlangen and the Government of Mittelfranken, Germany.
277 Animals were kept in 12 h dark–light cycle with free
278 access to standard chow (Altromin, Hamburg, Germany)
279 and water at the veterinary care facility of the University of
280 Erlangen Medical Center. All operations were performed
281 by experienced microsurgeons using a surgical microscope
282 (Karl Zeiss, Jena, Germany) under general anaesthesia with
283 Isoflurane (Baxter, Unterschleißheim, Germany).
284 The rats were divided into four groups, each consisting
285 of six animals. The PLDLLA–TCP–PCL scaffold was
286 loaded with 1 ml of HA hydrogel containing either of
287 500 ng rhBMP-2 (group A), 2.5 lg rhBMP-2 (group B), or
288 three million hydrogel-immobilized osteoblasts (group C)
289 prior to implantation. Scaffolds with plain HA hydrogel
290 served as controls (group D).
291 The surgical technique has been described previously by
292 our group [24]. In brief, the femoral vessels and nerve were
293 exposed by a longitudinal incision from the inguinal
294ligament to the knee. The sheath of the neurovascular
295bundle was opened. After exposure of the right-sided
296femoral vessels, a 20 mm vein graft was harvested from the
297right femoral vein. An A–V loop was created by interpo-
298sition of the vein graft between the left sided femoral artery
299and the left femoral vein with interrupted non-absorbable
30011-0 nylon stitches (Ethilon, Ethicon GmbH, Norderstedt,
301Germany). The A–V loop was placed around the PLD-
302LLA–TCP–PCL scaffold and the whole construct was
303placed into a sterile cylindrical Teflon-chamber (inner
304diameter 10 mm, height 6 mm, constructed by the Institute
305of Materials Research, Division of Glass and Ceramics,
306University of Erlangen). The chamber was then capped
307and fixed to the underlying muscle. The skin was closed
308using interrupted 3-0 vicryl sutures (Ethicon GmbH,
309Norderstedt, Germany). All animals received 0.2 ml ben-
310zylpenicillinbenzathine (Tardomycel; Bayer, Leverkusen,
311Germany), buprenorphine (0.3 mg/kg rat weight) (Tem-
312gesic; Essex Chemie AG, Luzern, Switzerland), and hep-
313arin (80 IU/kg) (Liquemin; Ratiopharm, Ulm, Germany)
314postoperatively.
315Explantation of the specimens was performed after
3168 weeks. For sacrifice, one specimen from each group was
317used for RNA isolation as described later. The other rats
318were perfused with Microfil under general anesthesia for
319micro-CT analysis. The aorta was cannulated and the
320vascular system was rinsed with heparinized Ringer solu-
321tion (100 IU/ml) under hydrostatic pressure. The distal
322vascular system was then injected with 20 ml microfil
323(MV-122) containing 5% of MV curing agent (both from
324Flowtech, MA, USA) as advised by the manufacturer.
325Finally the aorta and caval vein were ligated and the rats
326were cooled at 4C for 24 h. Specimens were explanted in
327toto and fixed in 3.5% formalin solution before micro-CT.
3282.5 Micro-CT analysis
329For each of the experimental groups, two specimens were
330selected at random for micro-CT analysis. To decalcify the
331scaffolds, the explanted grafts were treated with 20% EDTA
332for 3 weeks before further manipulation. They were sub-
333sequently scanned on a high resolution ‘‘ForBild’’ scanner
334(an in vivo micro computerized tomography (micro-CT)
335scanner developed by Institute of Medical Physics, FAU
336Erlangen-Nuremberg, Germany). The constructs were
337scanned with following parameters: Al-0.5 mm filter, tube
338voltage of 40 kV, 15 lm pixel size, and 15 lm slice dis-
339tance between consecutive slices. The data were volumet-
340rically re-constructed using ImpactView software (Vamp
341GmbH, Erlangen, Germany) in a 1024 9 1024 pixels
342matrix. Further, 3D modeling for data analysis was
343done using Mimics v8.02 software (Materialise, Leuven,
344Belgium). The different tissues were segmented according
J Mater Sci: Mater Med
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345 to their Hounsfield Unit values by global thresholding
346 procedure to selectively obliterate the scaffolds and soft
347 tissues. After 3D reconstruction, the volume and area of
348 microfil-perfused blood vessels were calculated. Using the
349 data, the mean number of vessels per unit length was cal-
350 culated, as described before [25].
351 2.6 Histology and histomorphometry
352 The samples were serially dehydrated and paraffin
353 embedded according to standard protocols. Five lm sec-
354 tions were taken using a microtome (Leica RM 2135,
355 Wetzlar, Germany). All the slides were stained with
356 Hematoxylin and eosin (H & E) using a fully automated
357 process (Jung Auto Stainer XL, Leica Microsystems,
358 Nussloch, Germany).
359 Immunhistochemical analysis was performed using
360 rabbit polyclonal antibodies against vWF (von-willebrand
361 factor) (A0082, Dakocytomation, Carpinteria, CA, USA)
362 at 1:500 dilution to confirm the vascular endothelium.
363 Envision HRP anti-rabbit kit (K4011, Dakocytomation,
364 Carpinteria, CA, USA) was used as secondary antibody.
365 The histomorphometric analysis was performed by two
366 blinded, independent observers as described elsewhere
367 [26]. Briefly, the images of two standardized planes
368 (500 lm proximal and 500 lm distal to the central plane)
369 were photographed and oriented perpendicular to the lon-
370 gitudinal axis of A–V loops. All images were taken by a
371 light microscope with bright-field filter (Leica DM IRB,
372 Wetzlar, Germany) and digital camera under 925 magni-
373 fication. The individual images of each cross section were
374 set together (Photoshop, Adobe, San Jose, CA, USA). The
375 composed images were rendered bimodal (ImageJ, NIH,
376 Bethesda, MA, USA). The construct size (cross-sectional
377 area) and the area of FVT were measured for each of the
378 sections. The percentage of fibro vascular tissue (% FVT)
379 was calculated by the ratio of total FVT area to total cross
380 sectional area of the specimen. The total number of blood
381 vessels was assessed by counting the microfil-filled (posi-
382 tive) vessels in ten pre-selected fields of view (four in the
383 central region and three each in upper and lower parts of
384 the construct) at 9100 magnification. Results are expressed
385 as means ± standard-errors of the mean.
386 2.7 RNA isolation and quantitative real time RT-PCR
387 After scarification of the animal, the chamber was quickly
388 isolated and kept overnight at 4C in RNAlater RNA
389 Stabilization Reagent (Qiagen, Hilden, Germany) and fur-
390 ther in -80C until RNA isolation. Total RNA was isolated
391 from the tissue grown in the loop using TRIzol Reagent
392 (Invitrogen, Carlsbad, CA, USA) followed by RNeasy Mini
393 Kit (Qiagen, Hilden, Germany) according to manufacturer’s
394protocol and RNA was measured by BioPhotometer
395(Eppendorf, Hamburg, Germany). Total RNA was con-
396verted to c-DNA using oligo d-T primers (Fermentas, Glen
397Burnie, MD, USA) and RevertAid H Minus M-MuLV
398Reverse Transcriptase (Fermentas, Glen Burnie, MD, USA).
399The amount of cDNA corresponding to 20 ng of total
400RNA was then analyzed in triplicates by semi-quantitative
401real time PCR for selected genes with primers as shown in
402Table 1 by Mx3000P QPCR System (Stratagene, Agilent
403technologies, La Jolla, CA, USA). The gene expressions
404were normalized to internal b-actin expression and the
405relative fold change was expressed by comparing to that of
406control group D.
4072.8 Statistical analysis
408Statistical comparisons were performed for histomorpho-
409metric analysis by a two-way ANOVA test followed by
410Bonferroni’s post-test (Sigmastat v3.5, Chicago, IL) con-
411sidering significant difference at the 95% confidence
412interval. Standard error bars were included in all graphs
413and represent the 95% confidence interval. For all pairwise
414comparisons on quantitative results the Student’s t-test was
415used with a confidence level of 95% (P\ 0.05).
4163 Results
4173.1 Osteoblasts in hyaluronan-based hydrogel in vitro
418At 4 and 8 weeks, osteoblasts were relatively distinct and
419well maintained throughout the hydrogel (Fig. 2a). How-
420ever, the thickness of the hydrogel decreased considerably
421over 8 weeks. Vitality of osteoblasts was demonstrated
422over the entire observation period by FDA/PI staining
423(Fig. 2b) while dead cells were almost non-existent.
424The metabolic activity of the cells increased progres-
425sively until week five followed by a decline by week eight
426(Fig. 2c). A similar trend was observed in the DNA
427quantification assay, where a significant decrease in
428dsDNA values between week four (35.38 ± 10.34) and
429week eight (7.57 ± 1.90) was demonstrated (Fig. 2d).
4303.2 Release kinetics of BMP-2 from hyaluronan-based
431hydrogel
432In vitro BMP-2 release from HA hydrogels was followed
433until day 35 (Fig. 3). The release kinetics of BMP-2 was
434characterized by a fast initial peak within the first 3 days
435followed by a sustained release over the course of 35 days.
436Even at the end of 5 weeks, a considerable percentage of
437BMP-2 was still incorporated inside hydrogel. Within the
438first 24 h, almost 10% of the loaded BMP-2 was released.
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439 Thereafter, the release rate was almost constant until the
440 end of observation.
441 3.3 Qualitative and quantitative micro-CT analysis
442 The pattern and distribution of angiogenesis of representa-
443 tive samples in micro-CT scanning are shown for scaffolds
444 with plain hydrogel (control group D, Fig. 4d), hydrogel
445 with low dose BMP-2 (500 ng, group A, Fig. 4a), hydrogel
446 with high dose BMP-2 (2.5 lg, group B, Fig. 4b), and
447 hydrogels containing osteoblasts (group C, Fig. 4c). In
Table 1 The primers of the
genes analyzed by real time
PCR
Gene name Forward primer Reverse primer
Alkaline phosphatase GCTGATCACTCCCACGTTTT GCTGTGAAGGGCTTCTTGTC
Biglycan CCACCAACTAACCAGCCTGT CAAGGTGAAGTCCCAGAAGC
Syndecan CTGATCCTGCTGCTGGTGTA TCATGCGTAGAACTCGTTGG
BMP 2 TGAACACAGCTGGTCTCAGG TTAAGACGCTTCCGCTGTTT
Osteocalcin CTATGGCACCACCGTTTAGG AGCTGTGCCGTCCATACTTT
Collagen 1 TTCTGAAACCCTCCCCTCTT CCACCCCAGGGATAAAAACT
Osteonectin AAACATGGCAAGGTGTGTGA AAGTGGCAGGAAGAGTCGAA
Agrrecan AACTCAGTGGCCAAACATCC AGATGTTCCCTCACCAGTGC
Collagen 2 CGAGGTGACAAAGGAGAAGC AGGGCCAGAAGTACCCTGAT
VEGF AATGATGAAGCCCTGGAGTG ATGCTGCAGGAAGCTCATCT
Beta-actin GATCATTGCTCCTCCTGAGC ACATCTGCTGGAAGGTGGAC
FGF 2 TTCTTTGAACGCCTGGAGTC CCGTTTTGGATCCGAGTTTA
Fig. 2 Osteoblasts in hyaluronic acid hydrogel after 4 weeks, exam-
ined in a inverted light microscope, and b after FDA/PI staining in
fluorescence microscope. Cells are evenly distributed within the
matrix and display a typical and differentiated morphology. There are
virtually no dead (PI-positive) cells. cMetabolic activity of osteoblasts
is demonstrated by AlamarBlue assay in hyaluronic acid hydrogel over
the observation period with a peak at week five. d The dsDNA value of
osteoblasts is significantly decreased at week eight compared to week
four as evidenced by PicoGreen assay (P\ 0.05)
Fig. 3 Cumulative release of rhBMP-2 from the hyaluronic acid
hydrogel over a period of 35 days
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448 groups A and D, blood vessels start sprouting from the A–V
449 loop into the centre of the scaffold. In group B, the newly
450 grown vessels already extend towards the centre of the
451 scaffold from all directions. However, only in group C
452 (osteoblast transplantation) there is extensive vascular
453 growth filling the entire centre of the scaffold (Fig. 4d).
454 The total volume of angiogenesis approached 5–10 mm
3
455 in control group D as well as groups A and B (low dose
456 BMP-2 and high dose BMP-2, respectively) (Fig. 5a).
457 However, in group C (osteoblast transplantation) the value
458 was 10–15 mm
3. As per the calculation by Bolland et al.
459 [25], the number of vessels per mm length in groups A, B,
460 and D is within 10–100, while one group C sample shows
461 187 per mm length (Fig. 5b). No further statistical analysis
462 of the micro-CT data was performed due to the limited
463 number of samples (Fig. 5b).
464 3.4 Histology and immunohistochemistry
465 Histological specimens showed numerous microfil-filled
466 blood vessels (black) in specimens from all groups.
467 A dense network of newly formed blood vessels originated
468 from the A–V loop and progressively invaded the void
469spaces within the scaffolds from all groups. However,
470BMP-2 concentration and transplantation of osteoblasts
471influenced the number of blood vessels and the volume of
472newly formed fibro-vascular tissue. A representative figure
Fig. 4 Micro-CT analysis. 3D
reconstructed images of
representative samples from
a group A (500 ng/ml BMP-2),
b group B (2.5 lg/ml BMP-2),
c group C (osteoblast
transplanted), and d group D
(control). Osteoblast
transplantation leads to
considerable increase in blood
vessel outgrowth from the A–V
loop
Fig. 5 Quantitative micro-CT analysis of specimens after 8 weeks
in vivo (n = 2 per group) showing a the volume of angiogenesis in
the isolation chamber, and b number of vessels per mm length
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473 of each type of sample is shown in Fig. 6: low concen-
474 tration of BMP-2 (group A, Fig. 6a), high concentration of
475 BMP-2 (group B, Fig. 6b), osteoblast transplantation
476 (group C, Fig. 6c), and scaffolds with plain hydrogel
477 (control group D, Fig. 6d). There was no significant foreign
478 body reaction detectable in specimens from any group and
479 the scaffolds were almost completely intact after 8 weeks.
480 In specimens from groups A, B, and D (low concentration
481 BMP, high concentration BMP and control, respectively),
482 there was some amount of non-resorbed hyaluronan matrix
483 observed after 8 weeks. In contrast, in specimens from
484 group C (osteoblast transplantation), the hydrogel compo-
485 nent was completely resorbed.
486 Immunostaining with vWF antibody specifically dem-
487 onstrated patency and functional integrity of blood vessels
488with microfil-filled (black) lumen in specimens from all
489groups (Fig. 6e, f). There was no significant bone forma-
490tion detectable in histological samples from any group.
4913.5 Histomorphometry
492The percentages of fibro vascular tissue (FVT) were for
493group A 12.57 ± 1.3, for group B 16.52 ± 0.7, for group
494C 24.14 ± 1.4, and for group D 16.28 ± 2.6, respectively.
495Similarly, the percentages of unresorbed hyaluronic acid
496matrix left at the end of 8 weeks were 15.34 ± 3.1,
4975.76 ± 1.0, 0 ± 0, and 13.62 ± 2.1 for groups A, B, C,
498and D, respectively. Interestingly, the entire hyalu-
499ronic acid hydrogel was resolved in group C (osteoblast
500transplantation) specimens. The percentage of FVT was
Fig. 6 Hematoxylin and eosin
staining of representative
specimens: a group A
(500 ng/ml BMP-2), b group B
(2.5 lg/ml BMP-2), c group C
(osteoblast), and d control group
D after 8 weeks. S scaffold, HA
hyaluronic acid matrix, BV
microfil-filled blood vessels,
FVT fibro vascular tissue, V vein
of the loop. All scale bars show
200 lm. (e and
f) Immunohistochemistry with
vWF antibody showing the
vascular architecture of group B
and group D, respectively. The
co-localization of vWF-positive
walls and microfil-filled lumen
clearly demonstrate functional
integrity of the newly grown
vasculature
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501 significantly higher (P\ 0.001) in samples from group C
502 in comparison to groups A, B, and D. The percentage of
503 hyaluronic acid hydrogel matrix values was significantly
504 lower in groups B and C compared to groups A and D.
505 The results are displayed graphically in Fig. 7a.
506 The total number of blood vessels per cross section area
507 was 95.57 ± 23.40, 66.40 ± 3.91, 138.7 ± 9.60, and
508 67.33 ± 12.03 in groups A, B, C, and D, respectively.
509 Specimens from the osteoblast transplantation group C
510 contained significantly more blood vessels than specimens
511 from groups B and D (P =\0.05) (Fig. 7b).
512 3.6 Quantitative real time RT-PCR
513 Bone-related gene expression profile is shown in Fig. 8.
514 Expression of collagen-I and osteonectin was not signifi-
515 cantly increased in the experimental groups A–C in
516 comparison to control group D. In contrast, alkaline
517 phosphatase, RUNX-2, osteocalcin, and IBSP expressions
518 were increased in groups A, B, and C (low-and high con-
519 centration BMP and osteoblast transplantation). However,
520 this effect was not statistically significant for all groups.
521 Expression profile for selected extracellular matrix
522 proteins and growth factors are shown in Fig. 9. Syndecan
523 expression was neither influenced by BMP-2 nor trans-
524 plantation of osteoblasts. Interestingly, biglycan expression
525 was increased in high-concentration BMP-2 and osteoblast
526 transplantation groups (groups B and C, P\ 0.05 only for
527 group B). The expression profile of growth factors such as
528 VEGF, FGF2, and BMP-2 was not significantly different in
529 the experimental groups A–C compared to control group D.
5304 Discussion
531This study clearly demonstrates that the hyaluronan-based
532matrix supported growth and differentiation of osteoblasts
533in vitro and in vivo and allowed sustained release of BMP-
5342. The whole system showed positive evidence of bone-
535related gene expression, though it eventually failed to
536induce significant amounts of bone histologically in an
537isolation chamber model of axial vascularization. Sum-
538marizing, PLDLLA–TCP–PCL polymer-ceramic compos-
539ite scaffolds combined with HA-based hydrogel might be
540utilized in engineering of bio-artificial bone tissues.
541Typical hydrogel systems are characterized by an initial
542higher peak of growth factor release followed by a reduced
543release later. At the beginning, there is maximal avail-
544ability of free growth factors for nearby cells [27, 28].
545Afterwards, two distinctive release patterns are seen for
546different hydrogels. In surface-eroding hydrogel, there
547follows a slow release later in time; while in bulk-eroding
548hydrogel, degradation and random release ensue [29].
549Though the hydrogel is required to bind BMP-2, the con-
550tinuous release must induce sufficient concentration in the
551vicinity to act on precursor cells to induce the specific
552action of the growth factor. In our study, a similar trend
553regarding the amount and rate of release of BMP-2 is seen
554at the beginning, followed by a very slow release rate until
5555 weeks. The final disintegration might have released all
556BMP-2 contained in the hydrogel.
557The hyaluronan hydrogel demonstrated in vitro growth
558compatibility with the osteoblasts and supported their rep-
559lication, as observed in light microscopic pictures and
560corroborated by AlamarBlue results until week five.
561Thereafter, the progressive decline in AlamarBlue assay
562might be due to gradual dissolution of hydrogel by hyal-
563uronidase secreted by osteoblasts with corresponding loss
564of cells [30]. This was substantiated by PicoGreen assay,
565where 8 week dsDNA was significantly lower than
5664 weeks. Cell death cannot account for the lowered values
567as all cells were found healthy and alive in FDA/PI staining.
568Successful vascularization of composite scaffolds was
569clearly demonstrated by micro-CT and histological analy-
570sis. In micro-CT angiograms, there was significant angio-
571genetic activity originating from the original A–V loop. In
572BMP groups (groups A and B), the proximal part of loops
573generally displayed comparatively more sprouting blood
574vessels than the distal part found interior in the chamber.
575This might be due to VEGF mediated vascularization by
576BMP-2 [31]. In osteoblast transplanted group C, there were
577a uniform extensive angiogenetic activity and formation of
578blood vessels throughout the chamber, even extending to
579the centers. The data were corroborated well by histo-
580morphometric analysis. The FVT area as well as the
581number of blood vessels was significantly increased in
Fig. 7 Histomorphometric calculations of blood vessel formation in
the graft constructs. a Mean percentage of FVT and non-resorbed
hyaluronic acid matrix. b Mean number of blood vessels per cross
section. Asterisks indicate statistically significant differences between
groups (P\ 0.05); group A 500 ng/ml BMP-2, group B 2.5 lg/ml
BMP-2, group C osteoblast transplantation, and group D control
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582 group C specimens. These findings might be explained by
583 faster resorption of hyaluronic acid following application
584 of osteoblasts [30]. This is supported by significantly lower
585 percentage of remaining hyaluronan matrix in group C
586 specimens (Fig. 7). The degradation byproducts may
587 stimulate angiogenesis subsequently [32]. Additionally, a
588strong hypoxic stimulus from cells may stimulate VEGF
589secretion [33].
590Contrary to the demonstration of extensive vasculari-
591zation, a clear histological evidence of bone formation
592could not be seen in the examined sections of our loop
593model. Researchers have tried BMP-2 dosage from 1 lg in
Fig. 8 Quantitative real time
RT-PCR analysis of bone-
related gene expression:
Collagen-I (a), alkaline
phosphatase (b), IBSP (c),
RUNX-2 (d), osteocalcin (e),
and osteonectin (f). Specific
gene expression was normalized
to internal b-actin expression.
Values represent the fold change
compared to control group D.
The error bar represents
standard deviation and the
asterisks indicate significant
differences between
experimental groups and control
group D (P = 0.05). Each bar
represents three independent
measurements. Group
A 500 ng/ml BMP-2, group
B 2.5 lg/ml BMP-2, group
C osteoblast transplantation,
and group D control
Fig. 9 Quantitative real time
RT-PCR analysis of
extracellular matrix and growth
factors expressions: Syndecan
(a), Biglycan (b), VEGF (c),
FGF-2 (d), and BMP-2 (e).
Specific gene expression was
normalized to internal b-actin
expression. Values represent the
fold change compared to control
group D. The error bar
represents standard deviation
and the asterisks indicate
significant differences between
experimental groups and control
group D (P = 0.05). Each bar
represents three independent
measurements. Group
A 500 ng/ml BMP-2, group
B 2.5 lg/ml BMP-2, group
C osteoblast transplantation,
and group D control
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594 hind-limb muscle and subcutaneous tissue to 50 lg in bone
595 defect sites in rats with successful bone induction [34, 35].
596 We have also demonstrated extensive bone formation his-
597 tologically after subcutaneous application of 2.5 lg of
598 BMP-2 after 8 weeks (data not shown). The absence of
599 bone histology in experimental specimens might be due to
600 ineffective dosage of BMP-2, which could only be
601 addressed empirically. The currently approved effective
602 dose with a collagen carrier requires BMP-2 in milligram
603 amounts, while in vivo the level is actually in nano to pico
604 molar range [17]. The higher BMP-2 dose might be nec-
605 essary for ectopic osteoinduction, where there is no readily
606 available effector tissue present.
607 Another reason might be the challenging properties of
608 the isolation chamber model. Since the newly grown tissue
609 was isolated from surrounding tissues except for the
610 communication through vascular loops, the model had
611 limited access to subcutaneous tissue. Previous studies in
612 our model demonstrated that the neo-angiogenesis and the
613 subsequent FVT invasion occur only after 2–4 weeks of
614 surgical loop placement [24]. Beforehand, there might be
615 no effector cells in the adjacent area. By this time, a large
616 percentage of BMP-2 must have been released and biode-
617 graded without any action. With its slow release phase after
618 2 weeks, the local concentration must be grossly inade-
619 quate in inducing ectopic bone. Observations by others
620 support this hypothesis, when they found that application
621 of BMP-2 at a delayed interval of 7 days after the time of
622 surgery resulted in a significantly increased osteogenic
623 induction [28] due to the increased number of BMP-2
624 responsive cells. However, in a separate study, fast release
625 of BMP was associated with increased new bone induction
626 over a short observation period, while a slow release was
627 not [27]. Consequently, it appears that it is the release
628 kinetics of BMP-2 with its net balance of effective con-
629 centration and degradation, which usually makes the dif-
630 ference. The release kinetic must be optimized for our
631 chamber model, where a peak release is required at the
632 time of rapid angiogenesis and FVT generation. Therefore,
633 specifically for this A–V loop model, we may need a higher
634 dosage of BMP-2 or later application during the course of
635 the experiment. In the future, we propose a 2 week delay
636 for BMP-2 application, where the burst release can be
637 synchronized with presumptive maximum vascular tissue
638 growth. Additionally, without proper mechanical stimula-
639 tion, it is unlikely to find significant amounts of mature
640 bone histologically or the induced bone might have even
641 resorbed [36].
642 In comparison to growth factors, co-culture systems are
643 attractive in addressing two components of a tissue such as
644 the osteogenic compartment and blood vessels in bone
645 tissue. Optimally, different cell components are capable of
646 inducing each other to a fully differentiated state. However,
647regarding applications in regenerative medicine, autolo-
648gous cells are the gold standard at the moment. Isolation
649and expansion of autologous cells under GMP conditions,
650which are mandatory for clinical application of bioartificial
651tissues, are technically demanding and rather expensive.
652Additionally, the bi-directional interaction of cells under
653co-culture conditions needs to be fully characterized. Large
654volume applications of bioartificial tissues are also ham-
655pered by significant initial cell loss if vascularization
656aspects are not considered. Growth factors such as BMPs
657might be utilized to enhance tissue formation and increase
658efficacy of cell based strategies [6]. Under certain condi-
659tions and in selected indications, they might even replace
660transplantation of cells if adequate release kinetics and
661material properties are provided.
662Though the histological cut sections showed no bone
663formation, semi-quantitative real time PCR results showed
664a different picture of gene expression. Groups A (500 ng
665BMP-2) and C (osteoblasts) had significantly higher
666expression of bone-related genes especially, osteocalcin
667and IBSP. Group A also showed significantly increased
668expression of alkaline phosphatase. Expression of these
669bone-related genes is important at different stages of bone
670maturation. As histological bone formation is a very
671complex phenomenon, which requires coordinated inter-
672play of different types of cells and growth factors, we
673assume that the osteo-inductive stimulus was sufficient to
674induce expression of bone-related genes but induction of
675bone formation eventually failed due to insufficient long-
676term concentration of BMPs and lack of effector cells. The
677expression of growth factors such as BMP-2, FGF-2, and
678VEGF were not significantly different at 8 weeks. Cell
679surface proteoglycans function in cell adhesion to cell or
680matrix. A higher expression of biglycan was found in group
681B (2.5 lg BMP-2), while there was no difference of
682Syndecan expression. Syndecan is ubiquitously expressed
683in all cells except for some bone-specific subtypes, while
684biglycan is highly expressed in bone morphogenesis [37].
685Cell mitosis can occur at pico molar range of BMP-2, while
686cell differentiation needs nano molar range [9]. When
687BMP-2 is sequestered in extracellular matrix, local con-
688centration might be higher to produce sporadic induction.
689This might explain the positive bone-related gene expres-
690sion while absence of any clearly demarcated histological
691bone.
692Although a well-vascularized scaffold is essential for the
693survival of osteoblasts, we have surprisingly found that the
694presence of cells is also crucial for development of
695extensive axial vascularization in a reciprocal manner.
696Therefore, the chamber model could be made porous in
697future by further modification to have access to the sur-
698rounding area, making both simultaneous extrinsic and
699axial vascularization possible at a very early stage.
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700 The approach may not only induce survival and faster
701 differentiation of osteoblasts but also stimulate in-growth
702 of new blood vessels. Moreover, application of angioge-
703 netic growth factors such as VEGF might have a similarly
704 stimulating effect. As discussed earlier, BMP-2 and oste-
705 oblasts might be applied in pre-vascularized scaffold after
706 2 weeks delay for their most efficient action, which is
707 currently under investigation by our group. Though such an
708 approach makes the model complex, it may ensure the
709 survival of cells and their differentiation from the
710 beginning.
711 At present, each of the individual components of PLD-
712 LLA–TCP–PCL and Extracel-HP is approved by the FDA.
713 Even so, as a whole group, the exact applicability of the
714 current approach needs to be demonstrated. It might utilize
715 a patient’s body as a bioreactor to make a tissue engineered
716 graft behave as an autograft to address the limitation of
717 autograft availability and the associated morbidity in their
718 procurement [11]. However, a number of issues must be
719 addressed before this kind of therapeutic strategy can be
720 applied.
721 In the future, BMP-2 loaded hydrogel might be highly
722 active on nearby MSCs if BMP-2 is applied after complete
723 growth of fibro-vascular tissue. Considering the well-
724 established biomaterials and the huge demand of vascular-
725 ized autografts in patients, a well-vascularized engineered
726 bone might satisfy the unmet demand. As a vein graft can be
727 utilized for induction of vascularization, this surgical
728 approach might eventually allow generation of axially
729 vascularized tissues with minimal donor site morbidity
730 independently of anatomic vascular axis.
731 5 Conclusion
732 In this study, we demonstrated that BMP-2 may be con-
733 tained within and slowly released from a Hyaluronan-based
734 hydrogel for more than 5 weeks. The hydrogel along with
735 PLDLLA–TCP–PCL scaffold could be axially vascularized
736 by an A–V loop. The hyaluronan hydrogel was gradually
737 degraded that guided sustained FVT growth and the
738 released BMP-2 induced bone-related gene expression,
739 although the formation of bone could not be observed
740 histologically. Based on the results of this experiment, it
741 can be concluded that the PLDLLA–TCP–PCL-hyaluronan
742 scaffold containing BMP-2 and supplied with an A–V loop
743 can possibly be explored as a well-vascularized bone graft
744 after further optimization.
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